Evaluation of Atacand® (Candesartan) in Daily Medical Practice

This open label, non-interventional study is to show the efficacy of antihypertensive treatment with Atacand in hypertensive patients. Efficacy is to be evaluated based on the difference in systolic and diastolic blood pressure at baseline and at both follow-up visits.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Hypertension Cardiovascular Diseases Vascular Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

a patient with arterial hypertension who has been prescribed Atacand according to physician's judgement, irrespective of the inclusion in the study

Exclusion criteria

hypersensitivity to candesartan or any other ingredient of Atacand
liver function impairment and/or cholestasis
severe renal insufficiency
woman of child-bearing potential and not using appropriate contraceptive measures, pregnancy or lactation

Treatment and study plan

Primary outcomes

Systolic and diastolic blood pressure reduction

Time frame: 12 weeks

Secondary outcomes

Incidence and reasons of treatment discontinuation

Time frame: 12 weeks
Patient treatment satisfaction (using 5-point answering scale) as the measure of the patient's overall tolerance

Time frame: 12 weeks
Physician overall evaluation of the therapy (using 5-point answering scale)

Time frame: 12 weeks

Sponsors and collaborators

Lead sponsor

AstraZeneca

Industry

Registry information

Official study title

A 12-Week Open-Label Non-Interventional Evaluation of Atacand® (Candesartan) Efficacy, Tolerability, Compliance and Treatment Satisfaction in Patients With Arterial Hypertension

Important dates

Study start: 2006
Study completion: 2007
First posted: Feb 5, 2009
Registry last updated: Feb 6, 2009

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed